RESUMEN
Etoposide is one of the most effective chemotherapeutic agents used in the treatment of various types of cancers. However, as a Topoisomerase II inhibitor, during clinical use, several side effects may occur. In addition, in several in vivo and in vitro studies, etoposide has been shown to have a range of genotoxic effects including single and double strand breaks. Melatonin is an anti-aging and antioxidant hormone synthesized from the pineal gland. The genoprotective, antioxidant, and free radical scavenger properties of melatonin have been well explained in various studies. The aim of this study was to explore whether melatonin nanoparticles protects against etoposide-induced genotoxicity in the HepG2 cell line. HepG2 cells (25 × 104 cells/well) were cultured in 24-well plates: a control group and 3 melatonin and its nanoparticles + etoposide groups (pre- and cotreatment conditions). Our results show that etoposide induced a noticeable genotoxic effect in HepG2 cells. Melatonin reduced the effects of etoposide significantly in both types of experiment conditions, through the reduction of the level of DNA damage measured via comet assay. Furthermore, melatonin decreased the intracellular reactive oxygen species generation. It also increased the intracellular glutathione levels in HepG2 cells. Nano melatonin is more effective than regular melatonin. The most protective effect was observed with melatonin when it was administrated 24 h before etoposide treatment.
Asunto(s)
Etopósido/antagonistas & inhibidores , Melatonina/farmacología , Línea Celular Tumoral , Quitosano/administración & dosificación , Quitosano/análogos & derivados , Glutatión/metabolismo , Humanos , Melatonina/administración & dosificación , Pruebas de Mutagenicidad , Nanopartículas/administración & dosificación , Especies Reactivas de Oxígeno/metabolismoRESUMEN
The current medical and surgical therapies for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease offer symptomatic relief but do not provide a cure. Thus, small synthetic compounds that protect neuronal cells from degeneration are critically needed to prevent and treat these. Oxidative stress has been implicated in various pathophysiological conditions, including neurodegenerative diseases. In a search for neuroprotective agents against oxidative stress using the murine hippocampal HT22â¯cell line, we found a novel oxindole compound, GIF-0726-r, which prevented oxidative stress-induced cell death, including glutamate-induced oxytosis and erastin-induced ferroptosis. This compound also exerted a protective effect on tunicamycin-induced ER stress to a lesser extent but had no effect on campthothecin-, etoposide- or staurosporine-induced apoptosis. In addition, GIF-0726-r was also found to be effective after the occurrence of oxidative stress. GIF-0726-r was capable of inhibiting reactive oxygen species accumulation and Ca2+ influx, a presumed executor in cell death, and was capable of activating the antioxidant response element, which is a cis-acting regulatory element in promoter regions of several genes encoding phase II detoxification enzymes and antioxidant proteins. These results suggest that GIF-0726-r is a low-molecular-weight compound that prevents neuronal cell death through attenuation of oxidative stress. Among the more than 200 derivatives of the GIF-0726-r synthesized, we identified the 11 most potent activators of the antioxidant response element and characterized their neuroprotective activity in HT22â¯cells.
Asunto(s)
Muerte Celular/efectos de los fármacos , Hipocampo/citología , Neuronas/citología , Neuronas/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Oxindoles/farmacología , Animales , Elementos de Respuesta Antioxidante/efectos de los fármacos , Apoptosis/efectos de los fármacos , Calcio/metabolismo , Camptotecina/antagonistas & inhibidores , Camptotecina/farmacología , Línea Celular , Etopósido/antagonistas & inhibidores , Etopósido/farmacología , Ratones , Neuronas/metabolismo , Fármacos Neuroprotectores/farmacología , Especies Reactivas de Oxígeno/metabolismo , Estaurosporina/antagonistas & inhibidores , Estaurosporina/farmacología , Tunicamicina/antagonistas & inhibidores , Tunicamicina/farmacologíaRESUMEN
Medicinal plants such as Aloe arborescens Miller and Aloe barbadensis Miller are used by the general population to treat various diseases. Therefore, the aim of this study was to evaluate the antimutagenicity of these two species using a methG1 system in Aspergillus nidulans and the comet assay in rats. The animals were treated with the plants at concentrations of 360 and 720 mg/kg body weight (1 and 2, respectively) by gavage for 14 days, followed by the administration of etoposide on treatment day 8. Blood samples were prepared for analysis of DNA damage. For the test in A. nidulans, the biA1methG1 lineage conidia were treated for 4 h with both plant species at concentrations of 4 and 8% (w/v). Then, they were washed and plated on a selective medium for frequency analysis of survival and mutation. The results of the comet assay showed that both plants were antigenotoxic compared to etoposide, which was not a typical response of methG1 systems, where only the highest concentration of plant extracts usually exhibit beneficial effects. This study demonstrates the potential antigenotoxicity and antimutagenicity of the Aloe plants tested and, therefore, supports their use as a form of preventive therapy and for health maintenance by the population.
Asunto(s)
Aloe/química , Aspergillus nidulans/efectos de los fármacos , ADN/química , Etopósido/antagonistas & inhibidores , Mutágenos/toxicidad , Extractos Vegetales/farmacología , Administración Oral , Animales , Aspergillus nidulans/crecimiento & desarrollo , Ensayo Cometa , ADN/genética , Daño del ADN , Etopósido/toxicidad , Masculino , Pruebas de Sensibilidad Microbiana , Pruebas de Mutagenicidad , Extractos Vegetales/aislamiento & purificación , Plantas Medicinales , Ratas , Ratas Wistar , Esporas Fúngicas/efectos de los fármacos , Esporas Fúngicas/crecimiento & desarrolloRESUMEN
Bromodomain-containing proteins are vital for controlling the expression of many pro-inflammatory genes. Consequently, compounds capable of inhibiting specific bromodomain-facilitated protein-protein interactions would be predicted to alleviate inflammation, making them valuable agents in the treatment of diseases caused by dysregulated inflammation, such as age-related macular degeneration. Here, we assessed the ability of known inhibitors JQ-1, PFI-1, and IBET-151 to protect from the inflammation and cell death caused by etoposide exposure in the human retinal pigment epithelial cell line, ARPE-19. The potential anti-inflammatory effects of the bromodomain inhibitors were assessed by ELISA (enzyme-linked immunosorbent assay) profiling. The involvement of NF-κB and SIRT1 in inflammatory signaling was monitored by ELISA and western blotting. Furthermore, SIRT1 was knocked down using a specific siRNA or inhibited by EX-527 to elucidate its role in the inflammatory reaction. The bromodomain inhibitors effectively decreased etoposide-induced release of IL-6 and IL-8. This anti-inflammatory effect was not related to SIRT1 activity, although all bromodomain inhibitors decreased the extent of acetylation of p53 at the SIRT1 deacetylation site. Overall, since bromodomain inhibitors display anti-inflammatory properties in human retinal pigment epithelial cells, these compounds may represent a new way of alleviating the inflammation underlying the onset of age-related macular degeneration.
Asunto(s)
Antiinflamatorios/farmacología , Compuestos de Azabiciclo/farmacología , Azepinas/farmacología , Benzodiazepinas/farmacología , Células Epiteliales/metabolismo , Etopósido/antagonistas & inhibidores , Piridinas/farmacología , Factores de Transcripción/antagonistas & inhibidores , Triazoles/farmacología , Carbazoles/farmacología , Línea Celular , Supervivencia Celular/efectos de los fármacos , Células Epiteliales/citología , Células Epiteliales/efectos de los fármacos , Etopósido/farmacología , Regulación de la Expresión Génica , Humanos , Inflamación , Interleucina-6/antagonistas & inhibidores , Interleucina-6/genética , Interleucina-6/metabolismo , Interleucina-8/antagonistas & inhibidores , Interleucina-8/genética , Interleucina-8/metabolismo , Modelos Biológicos , FN-kappa B/genética , FN-kappa B/metabolismo , Dominios Proteicos , ARN Interferente Pequeño/genética , ARN Interferente Pequeño/metabolismo , Epitelio Pigmentado de la Retina/citología , Epitelio Pigmentado de la Retina/efectos de los fármacos , Epitelio Pigmentado de la Retina/metabolismo , Transducción de Señal , Sirtuina 1/antagonistas & inhibidores , Sirtuina 1/genética , Sirtuina 1/metabolismo , Inhibidores de Topoisomerasa II/farmacología , Factores de Transcripción/genética , Factores de Transcripción/metabolismo , Proteína p53 Supresora de Tumor/genética , Proteína p53 Supresora de Tumor/metabolismoRESUMEN
Damage to DNA can lead to many different acute and chronic pathophysiological conditions, ranging from cancer to endothelial damage. The current study has been initiated to determine whether the flavonoid wogonin can attenuate etoposide-induced oxidative DNA damage and apoptosis in mouse bone marrow cells. We found that oral administration of wogonin before etoposide injection significantly attenuates etoposide-induced oxidative DNA damage and apoptosis in a dose dependent manner. Etoposide induced a significant down-regulation of mRNA expression of the OGG1 repair gene and marked biochemical alterations characteristic of oxidative DNA stress, including increased 8-OHdG, enhanced lipid peroxidation and reduction in reduced glutathione. Prior administration of wogonin ahead of etoposide challenge restored these altered parameters. Importantly, wogonin had no antagonizing effect on etoposide-induce topoisomerase-II inhibition. Conclusively, our study indicates that wogonin has a protective role in the abatement of etoposide-induced oxidative DNA damage and apoptosis in the bone marrow cells of mice via suppression of oxidative DNA stress and enhancing DNA repair through modulation of OGG1 repair gene expression. Therefore, wogonin can be a promising chemoprotective agent and might be useful to avert secondary leukemia and other drug-related cancers in cured cancer patients and medical personnel exposing to the potent carcinogen etoposide.
Asunto(s)
Células de la Médula Ósea/efectos de los fármacos , Daño del ADN/efectos de los fármacos , ADN Glicosilasas/metabolismo , Flavanonas/uso terapéutico , Regulación de la Expresión Génica/efectos de los fármacos , Leucemia/prevención & control , Estrés Oxidativo/efectos de los fármacos , Animales , Anticarcinógenos/administración & dosificación , Anticarcinógenos/efectos adversos , Anticarcinógenos/uso terapéutico , Antioxidantes/administración & dosificación , Antioxidantes/efectos adversos , Antioxidantes/uso terapéutico , Apoptosis/efectos de los fármacos , Células de la Médula Ósea/metabolismo , Células de la Médula Ósea/patología , ADN Glicosilasas/biosíntesis , ADN Glicosilasas/genética , Relación Dosis-Respuesta a Droga , Etopósido/efectos adversos , Etopósido/antagonistas & inhibidores , Flavanonas/administración & dosificación , Flavanonas/efectos adversos , Leucemia/inducido químicamente , Leucemia/metabolismo , Leucemia/patología , Masculino , Ratones , Pruebas de Micronúcleos , Pruebas de Mutagenicidad , ARN Mensajero/metabolismo , Distribución Aleatoria , Inhibidores de Topoisomerasa II/efectos adversos , Inhibidores de Topoisomerasa II/químicaRESUMEN
Emerging evidence implicates novel roles for post-translational prenylation (i.e., farnesylation and geranylgeranylation) of various signaling proteins in a variety of cellular functions including hormone secretion, survival and apoptosis. In the context of cellular apoptosis, it has been shown previously that caspase-3 activation, a hallmark of mitochondrial dysregulation, promotes hydrolysis of several key cellular proteins. We report herein that exposure of insulin-secreting INS 832/13 cells or normal rat islets to etoposide leads to significant activation of caspase-3 and subsequent degradation of the common α-subunit of farnesyl/geranylgeranyl transferases (FTase/GGTase). Furthermore, the above stated signaling steps were prevented by Z-DEVD-FMK, a known inhibitor of caspase-3. In addition, treatment of cell lysates with recombinant caspase-3 also caused FTase/GGTase α-subunit degradation. Moreover, nifedipine, a calcium channel blocker, markedly attenuated etoposide-induced caspase-3 activation, FTase/GGTase α-subunit degradation in INS 832/13 cells and normal rat islets. Further, nifedipine significantly restored etoposide-induced loss in metabolic cell viability in INS 832/13 cells. Based on these findings, we conclude that etoposide induces loss in cell viability by inducing mitochondrial dysfunction, caspase-3 activation and degradation of FTase/GGTase α-subunit. Potential significance of these findings in the context of protein prenylation and ß-cell survival are discussed.
Asunto(s)
Transferasas Alquil y Aril/metabolismo , Caspasa 3/metabolismo , Etopósido/antagonistas & inhibidores , Farnesiltransferasa/metabolismo , Células Secretoras de Insulina/metabolismo , Nifedipino/farmacología , Animales , Inhibidores de Caspasas/farmacología , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Etopósido/farmacología , Humanos , Células Secretoras de Insulina/efectos de los fármacos , Masculino , Oligopéptidos/farmacología , Prenilación de Proteína/efectos de los fármacos , Ratas , Ratas Sprague-DawleyRESUMEN
BACKGROUND AND OBJECTIVE: Chemokine receptor CCR7 is up-regulated in gastrointestinal carcinomas and is significantly associated with lymphatic invasion and lymph node metastasis. This study was to investigate the role and mechanism of CCL21/CCR7 in invasion of colorectal carcinoma cell line SW480. METHODS: The invasive capacity of SW480 cells was examined using Wound healing assay and Transwell assay. Expression of matrix metalloproteinase-9 (MMP-9) was measured by Western blot. SW480 cells were pre-incubated with CCL21 for 2 h before exposure to VP-16 (20 ng/mL). Cell proliferation was measured using MTT assay. Cell apoptosis was analyzed by flow cytometry and Hoechst33258 staining. RESULTS: Compared to the control group, more cells in the CCL21 treatment group migrated into the gap at same time points; the count of SW480 cells penetrating through the membrane after the treatment of 100ng/mL CCL21 increased significantly [(113+/-7) vs. (48+/-4)] (P<0.05); and the relative expression of MMP-9 in the CCL21 treatment group was enhanced evidently [(0.83+/-0.02) vs. (0.38+/-0.01)] (P<0.05). Although CCL21 alone did not promote proliferation of SW480 cells, pre-incubation of cells with 100ng/mL CCL21 attenuated the inhibitory effect of VP-16 on proliferation of SW480 from 68.3% to 47.4%, and reduced the apoptotic rate from (65.2+/-5.2)% to (48.7+/-3.1)%. CONCLUSION: CCL21 enhances the invasive ability of SW480 cells, induces MMP-9 expression, and promotes the survival of SW480 cells under the suboptimal circumstance in vitro.
Asunto(s)
Movimiento Celular/efectos de los fármacos , Quimiocina CCL21/farmacología , Neoplasias Colorrectales/patología , Receptores CCR7/metabolismo , Antineoplásicos Fitogénicos/antagonistas & inhibidores , Antineoplásicos Fitogénicos/farmacología , Apoptosis/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Neoplasias Colorrectales/metabolismo , Etopósido/antagonistas & inhibidores , Etopósido/farmacología , Humanos , Metaloproteinasa 9 de la Matriz/metabolismo , Invasividad NeoplásicaRESUMEN
The anthocyanidin delphinidin (DEL) has recently been shown to inhibit human topoisomerase I and II, without stabilizing the covalent DNA/topoisomerase intermediate [Habermeyer, M., Fritz, J., Barthelmes, H. U., Christensen, M. O., Larsen, M. K., Boege, F., and Marko, D. (2005) Anthocyanidins modulate the activity of human DNA topoisomerases I and II and affect cellular DNA integrity. Chem. Res. Toxicol. 18, 1395-404]. In the present study, we demonstrated that DEL affects the catalytic activity of topoisomerase IIalpha in a redox-independent manner. Furthermore, this potent inhibitory effect is not limited to a cell-free system, but is also of relevance within intact cells. DEL at micromolar concentrations was found to significantly decrease the level of topoisomerase IIalpha/DNA intermediates stabilized by the topoisomerase II poison doxorubicin in the human colon carcinoma cell line (HT29). In addition, DEL diminished the DNA-damaging properties of topoisomerase II poisons in HT29 cells without affecting the level of sites sensitive to formamidopyrimidine-DNA-glycosylase. However, the preventive effect on DNA damage exhibited an apparent maximum at a concentration of 10 microM DEL, followed by a recurrence of DNA damage at higher DEL concentrations. Furthermore, the incubation of HT29 cells with 10 microM DEL resulted in a decrease of etoposide (ETO)-induced DNA strand breaks. However, the level of ETO-stabilized covalent topoisomerase/DNA intermediates did not affect DEL, indicating an additional mechanism of action. An impact of DEL on genes involved in the repair of DNA double-strand breaks and the onset of apoptosis has to be considered. In conclusion, the natural food constituent DEL represents, depending on the concentration range, a protective factor against the DNA-damaging effects of topoisomerase II poisons in vitro. Further studies are needed to clarify whether in vivo a high DEL intake might compromise the therapeutic outcome of these anticancer agents.
Asunto(s)
Antocianinas/farmacología , Daño del ADN/efectos de los fármacos , Proteínas de Unión al ADN/antagonistas & inhibidores , Inhibidores Enzimáticos/toxicidad , Antígenos de Neoplasias , ADN-Topoisomerasas de Tipo II , Doxorrubicina/antagonistas & inhibidores , Doxorrubicina/química , Doxorrubicina/toxicidad , Inhibidores Enzimáticos/química , Etopósido/antagonistas & inhibidores , Etopósido/química , Etopósido/toxicidad , Células HT29 , Humanos , Estructura MolecularRESUMEN
Ornithine decarboxylase (ODC), the rate-limiting enzyme of the polyamine biosynthetic pathway, plays an important role in cell cycle, tumor promotion and anti-apoptosis. In our previous studies, overexpression of ODC prevented apoptosis induced by tumor necrosis factor-alpha and methotrexate. We further investigated the apoptotic mechanisms of the cancer chemotherapeutic drugs, including etoposide (VP-16), paclitaxel (TAX) and cisplatin (CDDP), and the influences of ODC on apoptosis and cell cycle. Our results showed that the investigated drugs induced caspase-dependent apoptosis, the generation of reactive oxygen species (ROS) and the disruption of mitochondrial membrane potential (Deltapsi m) in HL-60 cells, all of which were reversed by putrescine, glutathione or N-acetyl-l-cysteine. Overexpression of ODC prevented the cancer chemotherapeutic drugs-induced apoptosis, ROS generation and the disruption of Deltapsi m. After drug administrations, the decline of Bcl-2, cytochrome c release and caspases' activation were inhibited by ODC overexpression. In cell cycle, ODC overexpressed cells seemed to overcome the G1 arrest and G2/M arrest, caused by VP-16 and TAX, respectively, and kept on the cell cycle rolling. Overexpression of ODC increased the expression of Cyclin A, D, E and Cdk4 and the enzyme activity of Cdk1 and Cdk2 after the treatment of VP-16 and TAX, respectively. In conclusions, the cancer chemotherapeutic drugs-induced apoptosis is through ROS-related, mitochondria-mediated and caspase-dependent pathways. With higher ODC activity, cells are resistant to the cancer chemotherapeutic drugs-induced apoptosis and keep on the cell cycle rolling with the significant interference in G1/S arrest caused by VP-16 and G2/M arrest by TAX.
Asunto(s)
Antineoplásicos/antagonistas & inhibidores , Apoptosis , Leucemia/tratamiento farmacológico , Ornitina Descarboxilasa/metabolismo , Acetilcisteína/farmacología , Antineoplásicos/uso terapéutico , Apoptosis/efectos de los fármacos , Caspasas/metabolismo , Ciclo Celular , Cisplatino/antagonistas & inhibidores , Etopósido/antagonistas & inhibidores , Glutatión/farmacología , Células HL-60 , Humanos , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Paclitaxel/antagonistas & inhibidores , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Putrescina/farmacología , Especies Reactivas de Oxígeno/metabolismoRESUMEN
PR-39 is a cathelicidin with antimicrobial properties, which acts as a suppressor of inflammation and exerts a number of additional activities. We investigated for the first time the effect of PR-39 on human cells, by addressing the possible interference with HeLa cell metabolism. We observed that the continuous administration of PR-39 to HeLa cell cultures was not cytotoxic and did not interfere with DNA synthesis. When used in combination with a panel of drugs inducing apoptosis through different mechanisms of action, i.e. etoposide, bleomycin, tert-butylhydroperoxide and 2-deoxy-d-ribose, PR-39 attenuated the apoptotic response of HeLa cells.
Asunto(s)
Péptidos Catiónicos Antimicrobianos/farmacología , Apoptosis/efectos de los fármacos , Bleomicina/antagonistas & inhibidores , Supervivencia Celular/efectos de los fármacos , ADN/biosíntesis , Desoxirribosa/antagonistas & inhibidores , Etopósido/antagonistas & inhibidores , Células HeLa , Humanos , terc-Butilhidroperóxido/antagonistas & inhibidoresRESUMEN
Peroxynitrite is usually considered as a neurotoxic nitric oxide-derivative. However, an increasing body of evidence suggests that, at low concentrations, peroxynitrite affords transient cytoprotection, both in vitro and in vivo. Here, we addressed the signaling mechanism responsible for this effect, and found that rat cortical neurons in primary culture acutely exposed to peroxynitrite (0.1 mmol/L) rapidly elicited Akt-Ser(473) phosphorylation. Inhibition of phosphoinositide-3-kinase (PI3K)/Akt pathway with wortmannin or Akt small hairpin RNA (shRNA) abolished the ability of peroxynitrite to prevent etoposide-induced apoptotic death. Endogenous peroxynitrite formation by short-term incubation of neurons with glutamate stimulated Akt-Ser(473) phosphorylation, whereas Akt shRNA enhanced the vulnerability of neurons against glutamate. We further show that Akt-Ser(473) phosphorylation was consequence of the oxidizing, but not the nitrating properties of peroxynitrite. Peroxynitrite failed to nitrate or phosphorylate neurotrophin tyrosine kinase receptors (Trks), and it did not modify the ability of brain-derived neurotrophic factor (BDNF), to phosphorylate its cognate receptor, TrkB; however, peroxynitrite enhanced BDNF-mediated Akt-Ser(473) phosphorylation. Finally, we found that peroxynitrite-stimulated Akt-Ser(473) phosphorylation was associated with an increased proportion of oxidized phosphoinositide phosphatase, PTEN, in neurons. Moreover, peroxynitrite prevented the increase of apoptotic neuronal death caused by over-expression of PTEN. Thus, peroxynitrite exerts neuroprotection by inhibiting PTEN, hence activating the anti-apoptotic PI3K/Akt pathway in primary neurons.
Asunto(s)
Fármacos Neuroprotectores/farmacología , Proteína Oncogénica v-akt/metabolismo , Fosfohidrolasa PTEN/antagonistas & inhibidores , Ácido Peroxinitroso/farmacología , Fosfatidilinositol 3-Quinasas/metabolismo , Transducción de Señal/efectos de los fármacos , Antineoplásicos Fitogénicos/antagonistas & inhibidores , Antineoplásicos Fitogénicos/farmacología , Apoptosis/efectos de los fármacos , Western Blotting , Células Cultivadas , Corteza Cerebral/citología , Corteza Cerebral/efectos de los fármacos , Etopósido/antagonistas & inhibidores , Etopósido/farmacología , Citometría de Flujo , Humanos , Inmunoprecipitación , NADP/metabolismo , Degeneración Nerviosa/prevención & control , Oxidación-Reducción , Ácido Peroxinitroso/síntesis química , Fosforilación , Plásmidos/genética , ARN/biosíntesis , ARN/genética , TransfecciónRESUMEN
BACKGROUND AND PURPOSE: 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) are frequently used lipid-lowering drugs. Moreover, they exert pleiotropic effects on cellular stress responses and death. Here, we analysed whether lovastatin affects the sensitivity of primary human endothelial cells (HUVEC) to the anticancer drug doxorubicin. EXPERIMENTAL APPROACH: We investigated whether pretreatment of HUVEC with low dose of lovastatin influences the cellular sensitivity to doxorubicin. To this end, cell viability, proliferation and apoptosis as well as DNA damage-triggered stress response were analysed. KEY RESULTS: Lovastatin reduced the cytotoxic potency of doxorubicin in HUVEC. Lovastatin attenuated the doxorubicin-induced increase in p53 as well as activation of checkpoint kinase (Chk-1) and stress-activated protein kinase/c-Jun-N-terminal kinase (SAPK/JNK). Acquired doxorubicin resistance was independent of alterations in doxorubicin efflux and cell cycle progression. Also, doxorubicin-triggered production of reactive oxygen species (ROS) and formation of oxidative DNA lesions remained unaffected by lovastatin. However, lovastatin impaired DNA strand break formation induced by doxorubicin. Notably, lovastatin also conferred cross-resistance to the cytotoxic and genotoxic effects of etoposide, indicating that lovastatin shields topoisomerase II against poisons. CONCLUSIONS AND IMPLICATIONS: Based on these data, we suggest that lovastatin-mediated resistance to topoisomerase II inhibitors is due to a reduction in DNA damage and, hence, it attenuates stress responses leading to cell death that are triggered by DNA damage. Therefore, lovastatin might be useful clinically for alleviating side-effects of anticancer therapies that include topoisomerase II inhibitors.
Asunto(s)
Antibióticos Antineoplásicos/antagonistas & inhibidores , Antibióticos Antineoplásicos/toxicidad , Antimutagênicos , Antineoplásicos Fitogénicos/antagonistas & inhibidores , Antineoplásicos Fitogénicos/toxicidad , Doxorrubicina/antagonistas & inhibidores , Doxorrubicina/toxicidad , Células Endoteliales/efectos de los fármacos , Etopósido/antagonistas & inhibidores , Etopósido/toxicidad , Inhibidores de Hidroximetilglutaril-CoA Reductasas/farmacología , Lovastatina/farmacología , Antibióticos Antineoplásicos/metabolismo , Apoptosis/efectos de los fármacos , Ciclo Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Daño del ADN/efectos de los fármacos , Replicación del ADN/efectos de los fármacos , Doxorrubicina/metabolismo , Resistencia a Antineoplásicos , Fibroblastos/metabolismo , Fluoresceína-5-Isotiocianato , Colorantes Fluorescentes , Humanos , Especies Reactivas de Oxígeno/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Inhibidores de Topoisomerasa IIRESUMEN
Aspirin displays, at millimolar concentrations, several mechanisms independent from its ability to inhibit cyclooxygenases. Occasionally, the mechanisms displayed in vitro have been clearly related to an effect of clinical relevance in vivo. An expanding literature has been focusing on the cytoprotective effect of aspirin in neurodegenerative disorders and the activation of AKT pathway in neuroprotection and induction of resistance to anticancer drugs. In this work, we tested the ability of aspirin to activate the AKT survival pathway in methylcholanthrene-induced fibrosarcoma cells (Meth A) transplanted into BALB/c nude mice and the clinical effect of aspirin cotreatment during etoposide (VP-16)-based anticancer therapy. We found that cotreatment with aspirin reduced VP-16-induced apoptosis and activated AKT in vitro and in vivo. In Meth A-bearing mice, aspirin administration also activated glycogen synthase kinase-3 and reduced the activity and the efficacy of anticancer therapy in VP-16 cotreated animals. Our data suggest that the antiapoptotic effect of aspirin operates in vivo through the activation of AKT-glycogen synthase kinase pathway causing a decrease in the outcome of VP-16-based therapy. These findings could have clinical relevance in treatment of human malignancies.
Asunto(s)
Antineoplásicos Fitogénicos/antagonistas & inhibidores , Aspirina/farmacología , Etopósido/antagonistas & inhibidores , Glucógeno Sintasa Quinasas/metabolismo , Neoplasias Experimentales/tratamiento farmacológico , Proteínas Proto-Oncogénicas c-akt/metabolismo , Animales , Antiinflamatorios no Esteroideos/metabolismo , Antiinflamatorios no Esteroideos/farmacología , Antineoplásicos Fitogénicos/uso terapéutico , Aspirina/metabolismo , Etopósido/uso terapéutico , Femenino , Fibrosarcoma/inducido químicamente , Fibrosarcoma/metabolismo , Metilcolantreno , Ratones , Ratones Endogámicos BALB C , Trasplante de Neoplasias , Fosfatidilinositol 3-Quinasas/metabolismo , Transducción de Señal/efectos de los fármacos , Factores de Tiempo , Células Tumorales CultivadasRESUMEN
In this study, we investigated the influence of platelet-activating factor (PAF) on the induction of apoptosis-regulating factors in B16F10 melanoma cells. PAF increased the expression of mRNA and the protein synthesis of antiapoptotic factors, such as Bcl-2 and Bcl-xL, but did not increase the expression of the proapoptotic factor, Bax. A selective nuclear factor-kappaB (NF-kappaB) inhibitor, parthenolide, inhibited the effects of PAF. Furthermore, PAF inhibited etoposide-induced increases in caspase-3, caspase-8, and caspase-9 activities, as well as cell death. p50/p65 heterodimer increased the mRNA expression of Bcl-2 and Bcl-xL and decreased etoposide-induced caspase activities and cell death. In an in vivo model in which Matrigel was injected s.c., PAF augmented the growth of B16F10 cells and attenuated etoposide-induced inhibition of B16F10 cells growth. These data indicate that PAF induces up-regulation of antiapoptotic factors in a NF-kappaB-dependent manner in a melanoma cell line, therefore suggesting that PAF may diminish the cytotoxic effect of chemotherapeutic agents.
Asunto(s)
Proteínas Reguladoras de la Apoptosis/biosíntesis , Melanoma Experimental/metabolismo , FN-kappa B/metabolismo , Factor de Activación Plaquetaria/farmacología , Animales , Apoptosis/efectos de los fármacos , Apoptosis/fisiología , Proteínas Reguladoras de la Apoptosis/genética , Inhibidores de Caspasas , Caspasas/metabolismo , Línea Celular Tumoral , Interacciones Farmacológicas , Etopósido/antagonistas & inhibidores , Etopósido/farmacología , Femenino , Melanoma Experimental/tratamiento farmacológico , Melanoma Experimental/patología , Ratones , Ratones Endogámicos C57BL , FN-kappa B/antagonistas & inhibidores , Factor de Activación Plaquetaria/antagonistas & inhibidores , Proteínas Proto-Oncogénicas c-bcl-2/biosíntesis , Proteínas Proto-Oncogénicas c-bcl-2/genética , ARN Mensajero/biosíntesis , ARN Mensajero/genética , Sesquiterpenos/farmacología , Regulación hacia Arriba/efectos de los fármacos , Proteína X Asociada a bcl-2/biosíntesis , Proteína X Asociada a bcl-2/genética , Proteína bcl-X/biosíntesis , Proteína bcl-X/genéticaRESUMEN
Lithium confers cell protection against stress and toxic stimuli. Although lithium inhibits a number of enzymes, the antiapoptotic mechanisms of lithium remain unresolved. Here, we report a novel role of lithium on the blockage of ceramide- and etoposide-induced apoptosis via inhibition of protein phosphatase 2A (PP2A) activity. Overexpression of PP2A resulted in caspase-2 activation, mitochondrial damage, and cell apoptosis that were inhibited by okadaic acid (OA) and lithium. Lithium and OA abrogated ceramide- and etoposide-induced Bcl-2 dephosphorylation at serine 70. Furthermore, ceramide- and etoposide-induced PP2A activation involved methylation of PP2A C subunit, which lithium suppressed. Lithium caused dissociation of PP2A B subunit from the PP2A core enzyme, whereas ceramide caused recruitment of the B subunit. Taken together, lithium exhibited an antiapoptotic effect by inhibiting Bcl-2 dephosphorylation and caspase-2 activation, which involved, at least in part, a mechanism of down-regulating PP2A methylation and PP2A activity.
Asunto(s)
Apoptosis/efectos de los fármacos , Caspasas/metabolismo , Ceramidas/antagonistas & inhibidores , Etopósido/antagonistas & inhibidores , Litio/farmacología , Fosfoproteínas Fosfatasas/antagonistas & inhibidores , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Animales , Caspasa 2 , Células Cultivadas , Activación Enzimática/efectos de los fármacos , Metilación , Ratones , Fosfoproteínas Fosfatasas/química , Fosfoproteínas Fosfatasas/metabolismo , Fosforilación , Proteína Fosfatasa 2 , Subunidades de ProteínaRESUMEN
Paget's disease (PD) of bone is a chronic focal skeletal disorder characterized by excessive bone resorption followed by abundant new bone formation. Enhanced levels of IL-6, RANKL, M-CSF, and endothelin-1 have been associated with PD. In the present study, we identified increased serum levels (2 to 5-fold) of inflammatory cytokine, kininogen (KNG) in patients with PD compared to normal subjects. Treatment of pagetic bone marrow derived stromal/preosteoblast cells with recombinant KNG (25 ng/ml) for 24 h period resulted in a 5-fold increase in the levels of phospho-HSP27 and a 3-fold increase in ERK1/2 phosphorylation in these cells. However, pagetic stromal cells stimulated with KNG in the presence of ERK activation inhibitor peptide did not significantly affect the levels of phospho-HSP27. KNG increased normal and pagetic marrow stromal cell proliferation at 1.4-fold and 2.5-fold, respectively. KNG in the presence of an ERK inhibitor peptide did not stimulate pagetic marrow stromal cell proliferation. Furthermore, siRNA suppression of HSP27 expression significantly decreased KNG inhibition of etoposide-induced caspase-3 activation and apoptosis in these cells. In summary, KNG modulate bone marrow derived stromal/preosteoblast cell proliferation and suppress etoposide-induced apoptosis through ERK and HSP27 activation, respectively. These results implicate a pathophysiologic role for KNG in patients with PD.
Asunto(s)
Quininógenos/sangre , Quininógenos/farmacología , Osteítis Deformante/metabolismo , Apoptosis , Células de la Médula Ósea , Proliferación Celular , Células Cultivadas , Relación Dosis-Respuesta a Droga , Etopósido/antagonistas & inhibidores , Etopósido/farmacología , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Proteínas de Choque Térmico HSP27 , Proteínas de Choque Térmico/metabolismo , Humanos , Chaperonas Moleculares , Proteínas de Neoplasias/metabolismo , Fosforilación , ARN Interferente PequeñoRESUMEN
PURPOSE: Monoclonal antibodies, such as herceptin and trastuzumab, against the epidermal growth factor receptor ErbB2 (also known as HER2/neu) are an effective therapy for breast cancer patients with overexpression of ErbB2. Herceptin, in combination with standard chemotherapy, such as taxol or etoposide, gives a synergistically apoptotic response in breast tumors. EXPERIMENTAL DESIGN: The mechanism underlying this synergy between chemotherapy and herceptin treatment is not well understood. Herein, we have determined that addition of herceptin, sensitized breast cancer cell lines MDA-MB-231 and MCF-7 to etoposide- or taxol-induced apoptosis. RESULTS: This treatment resulted in reduced expression of ErbB2 and the antiapoptotic Bcl-2 family member Mcl-1 in MDA-MB-231 cells. Using antisense oligonucleotides against Mcl-1, MDA-MB-231 cells were rendered sensitive to etoposide-induced apoptosis similar to herceptin, but combined treatment of antisense against Mcl-1 and herceptin failed to give a significant increase in apoptosis. In 29 human breast tumors immunostained for ErbB2 and Mcl-1, we found that when ErbB2 was overexpressed, there was a corresponding increase in Mcl-1 expression. DISCUSSION: Using murine fibroblasts that express human ErbB2, but no other ErbB family member (NE2), these cells showed resistance to both taxol- and etoposide-induced apoptosis compared with parental cells. In addition, NE2 cells preferentially express the antiapoptotic Bcl-2 family member Mcl-1 compared with parental cells, and treatment with herceptin reduces Mcl-1 expression. Taken together, these results suggest that herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 protein levels.
Asunto(s)
Anticuerpos Monoclonales/farmacología , Apoptosis/efectos de los fármacos , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Genes erbB-2/efectos de los fármacos , Proteínas de Neoplasias/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Animales , Anticuerpos Monoclonales Humanizados , Línea Celular Tumoral , Etopósido/antagonistas & inhibidores , Etopósido/farmacología , Genes erbB-2/genética , Humanos , Ratones , Proteína 1 de la Secuencia de Leucemia de Células Mieloides , Proteínas de Neoplasias/efectos de los fármacos , Proteínas de Neoplasias/genética , Oligorribonucleótidos Antisentido/farmacología , Paclitaxel/farmacología , Proteínas Proto-Oncogénicas c-bcl-2/efectos de los fármacos , Proteínas Proto-Oncogénicas c-bcl-2/genética , Sensibilidad y Especificidad , Trastuzumab , Células Tumorales CultivadasRESUMEN
Digitoxin is used in the treatment of cardiac congestion and some types of cardiac arrhythmias. The mechanism of action of this cardiac glycoside suggested that it might antagonize the anticancer activity of topoisomerase II poisons. The present report shows that digitoxin, at concentrations commonly found in the plasma of cardiac patients, significantly reduced etoposide and idarubicin-induced topoisomerase II cleavable complexes in K562 leukemia cells. This may lead to a reduction in the anticancer effect of these two topoisomerase II poisons when they are used in the clinic concurrently with digitoxin.
Asunto(s)
Antineoplásicos/farmacología , Digitoxina/farmacología , Etopósido/antagonistas & inhibidores , Idarrubicina/antagonistas & inhibidores , Leucemia Mielógena Crónica BCR-ABL Positiva/tratamiento farmacológico , Inhibidores de Topoisomerasa II , Amsacrina/farmacología , Relación Dosis-Respuesta a Droga , Ensayos de Selección de Medicamentos Antitumorales , Etopósido/farmacología , Humanos , Idarrubicina/farmacología , Células K562 , Mitoxantrona/farmacología , Relación Estructura-ActividadRESUMEN
Rho GDP dissociation inhibitor (RhoGDI) plays an essential role in control of a variety of cellular functions through interactions with Rho family GTPases, including Rac1, Cdc42, and RhoA. RhoGDI is frequently overexpressed in human tumors and chemo-resistant cancer cell lines, raising the possibility that RhoGDI might play a role in the development of drug resistance in cancer cells. We found that overexpression of RhoGDI increased resistance of cancer cells (MDA-MB-231 human breast cancer cells and JLP-119 lymphoma cells) to the induction of apoptosis by two chemotherapeutic agents: etoposide and doxorubicin. Conversely, silencing of RhoGDI expression by DNA vector-mediated RNA interference (small interfering RNA) sensitized MDA-MB-231 cells to drug-induced apoptosis. Resistance to apoptosis was restored by reintroduction of RhoGDI protein expression. The mechanism for the anti-apoptotic activity of RhoGDI may derive from its ability to inhibit caspase-mediated cleavage of Rac1 GTPase, which is required for maximal apoptosis to occur in response to cytotoxic drugs. Taken together, the data show that RhoGDI is an anti-apoptotic molecule that mediates cellular resistance to these chemotherapy agents.
Asunto(s)
Apoptosis/fisiología , Neoplasias de la Mama/patología , Doxorrubicina/antagonistas & inhibidores , Etopósido/antagonistas & inhibidores , Inhibidores de Disociación de Guanina Nucleótido/fisiología , Linfoma/patología , Antibióticos Antineoplásicos/antagonistas & inhibidores , Antibióticos Antineoplásicos/farmacología , Antineoplásicos Fitogénicos/antagonistas & inhibidores , Antineoplásicos Fitogénicos/farmacología , Apoptosis/efectos de los fármacos , Secuencia de Bases , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/genética , Neoplasias de la Mama/metabolismo , Caspasa 3 , Inhibidores de Caspasas , Caspasas/metabolismo , Línea Celular Tumoral , Doxorrubicina/farmacología , Resistencia a Antineoplásicos , Etopósido/farmacología , Inhibidores de Disociación de Guanina Nucleótido/biosíntesis , Inhibidores de Disociación de Guanina Nucleótido/deficiencia , Inhibidores de Disociación de Guanina Nucleótido/genética , Humanos , Linfoma/tratamiento farmacológico , Linfoma/genética , Linfoma/metabolismo , Datos de Secuencia Molecular , Mutación , Interferencia de ARN , ARN Interferente Pequeño/genética , Transfección , Proteína de Unión al GTP rac1/biosíntesis , Proteína de Unión al GTP rac1/genética , Proteína de Unión al GTP rac1/metabolismo , Inhibidor alfa de Disociación del Nucleótido Guanina rho , Inhibidores de la Disociación del Nucleótido Guanina rho-EspecíficoRESUMEN
Osteocyte viability may play a significant role in the maintenance and integrity of bone. Bone loss due to osteoporosis may be due in part to osteocyte cell death. We have identified a factor that will protect both osteoblasts and osteocytes from cell death due to agents known to be responsible for various forms of osteoporosis. Not only does estrogen preserve osteoblast and osteocyte viability, but so does a molecule called CD40Ligand. This molecule is expressed on activated T lymphocytes, human dendritic cells, and human vascular endothelial cells, whereas its receptor CD40 is expressed on normal epithelium, B cells, and dendritic cells. CD40Ligand protects osteoblasts and the MLO-Y4 osteocyte-like cells against apoptosis induced by glucocorticoids, tumor necrosis factor alpha or etoposide. As tumor necrosis factor a has been shown to be responsible for post-menopausal bone loss and glucocorticoids induce dramatic bone loss, this finding has important implications with regards to potential therapy for both post-menopausal and steroid-induced osteoporosis.